An Adjunct Study to Assess Guided ADHD Therapy for Managing the Extent and Severity of Symptoms

NCT05805176 | Active Not Recruiting

• 1 other identifier: CIP-014
• Study Type: interventional
• Target: 194
• Locations: 1 country
• Sites: 5

Brief Summary

The objective of this study is to assess the safety and effectiveness of an at-home, game-based digital therapy for treating adult patients with Attention-Deficit/Hyperactivity Disorder (ADHD).

Conditions

ADHD

Outcome Measures

Primary Outcomes (1)

• Conners' Adult ADHD Rating Scales-Investigator Rated: Long Version (CAARS-Inv:L) Inattentive Symptoms subscale

  The Conners' Adult ADHD Rating Scales-Investigator Rated: Long Version (CAARS-Inv:L) has 66 items with multiple subscales.

  Study Day 0 to Study Day 63

Secondary Outcomes (3)

• Adult ADHD Self-Report Scale (ASRS) Inattentive Symptoms Subscale

  Study Day 0 to Study Day 63

• Conners' Adult ADHD Rating Scales-Investigator Rated: Long Version (CAARS-Inv:L) ADHD Symptoms Total subscale

  Study Day 0 to Study Day 63

• Sheehan Disability Scale (SDS)

  Study Day 0 to Study Day 63

Study Arms (1)

ADHD Therapy

EXPERIMENTAL

Device: ADHD Therapy

Interventions

ADHD Therapy DEVICE

investigational game-play therapy

ADHD Therapy

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• years of age (Cohort I) or 18-21 years of age (Cohort II)
• Confirmed ADHD diagnosis, combined or inattentive type, at Screening based on DSM-5 criteria and established via the MINI-Adult, administered by a trained clinician
• Baseline total score on the DSM 5 Inattentive Symptoms, DSM 5 Hyperactive - Impulsive Symptoms and ADHD Index subscales of the Conners' Adult ADHD Rating Scales-Investigator Rated: Long Version (CAARS-Inv:L) ≥24
• Current, stable use of an FDA approved pharmacological treatment for ADHD for at least 4 weeks prior to screening, but ADHD condition inadequately managed by that medication
• Ability to understand and speak English, follow written and verbal instructions (English), as assessed by the PI and/or Study Coordinator, and give informed consent (English)
• Have ability to connect wireless devices to a functional wireless network daily
• Have access to a computer or smart device (e.g., phone, tablet) with internet access and a Google Chrome web browser
• Ability to comply with all the testing and study requirements

You may not qualify if:

• Unstable/uncontrolled, comorbid psychiatric diagnosis, based on clinical interviewing, with significant current active symptoms including but not limited to posttraumatic stress disorder, schizophrenia spectrum and other psychotic disorders, bipolar disorder, autism spectrum disorder, severe obsessive-compulsive disorder, severe depressive or severe anxiety disorder, conduct disorder, or other symptomatic manifestations that in the opinion of the Investigator may confound study data/assessments
• Inadequate IQ to participate in the study as estimated by Investigator (i.e., inability to read/understand the informed consent; inability to understand how the device and therapy (games) work)
• PHQ-9 scores ≥16
• Have previously been assessed by TOVA for potential enrollment in a clinical trial.
• Have previously used a videogame-like digital therapy (e.g., Akili EndeavorRxTM) OR within the last three years, have used a cognitive or brain training platform (e.g., Peak, Brain HQ, Lumosity, Atentiv) for more than two weeks duration
• Known sensitivity to playing video games, such as headaches, dizziness, nausea
• Initiation within the last 4 weeks of behavioral therapy or neurofeedback, or planned initiation during the study. Patients who have been in behavior therapy or neurofeedback consistently for more than 4 weeks may participate provided their routine is unchanged during the course of the study. Patients planning on changing or initiating behavior therapy or neurofeedback during the course of the study will be excluded
• Patient is currently considered a suicide risk in the opinion of the Investigator, as measured by C-SSRS at screening (i.e., score of 4 or 5 on C-SSRS)
• Motor condition (e.g., physical deformity of the hands/arms; protheses) that prevents game playing as observed by the Investigator
• Recent history (within the past 12 months) of suspected alcohol or substance abuse or dependence
• Positive urine drug screen
• History of seizures (excluding febrile seizures), or significant motor or vocal tics, including but not limited to Tourette's Disorder and photo-sensitive epilepsy
• Visual acuity that cannot be corrected that prevents or negatively impacts game playing as observed by the Investigator
• Any use of psychoactive drugs (other than ADHD medication) that in the opinion of the Investigator may confound study data/assessments
• Has participated in a clinical trial within 90 days prior to screening

Sponsors & Collaborators

• Lumos Labs, Inc.: lead

Study Sites (5)

CNS Healthcare of Jacksonville

Jacksonville, Florida, 32256, United States

Location

Accel Clinical Research Sites

Lakeland, Florida, 33803, United States

Location

Rochester Center for Behavioral Medicine (RCBM)

Rochester Hills, Michigan, 48307, United States

Location

Midwest Research Group

Brentwood, Missouri, 63144, United States

Location

Hassman Research Institute

Berlin, New Jersey, 08009, United States

Location

MeSH Terms

Conditions

Attention Deficit Disorder with Hyperactivity

Condition Hierarchy (Ancestors)

Attention Deficit and Disruptive Behavior Disorders; Neurodevelopmental Disorders; Mental Disorders

Study Officials

• Greg Mattingly, MD

  Midwest Research Group

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 24, 2023
• First Posted: April 7, 2023
• Study Start: April 15, 2023
• Primary Completion: March 1, 2025
• Study Completion: June 1, 2025
• Last Updated: December 31, 2024

Record last verified: 2024-12

Data Sharing

• IPD Sharing: Will not share

Locations

US (5)